Brief: Theratechnologies Receives FDA Agreement To Amended Trial Protocol For Its Lead Pdc Candidate Sudocetaxel Zendusortide

Theratechnologies

02/06/2023 17:36

June 2 (Reuters) - Theratechnologies Inc  TH.TO :
    * THERATECHNOLOGIES RECEIVES FDA AGREEMENT TO AMENDED TRIAL
PROTOCOL FOR ITS LEAD PDC CANDIDATE SUDOCETAXEL ZENDUSORTIDE
    * THERATECHNOLOGIES INC - PHASE 1 TRIAL TO RESUME WITH
WEEKLY
DOSING, A FOCUS ON PATIENTS WITH OVARIAN CANCER AND REFINED
PATIENT SELECTION
    * THERATECHNOLOGIES INC - TODAY'S ANNOUNCEMENT ALSO MARKS
LIFTING
OF FDA'S PARTIAL CLINICAL HOLD ON PHASE 1 TRIAL

Source text for Eikon:  ID:nGNX75zZKk 
Further company coverage:  TH.TO 

 ((Reuters.Briefs@thomsonreuters.com;))